Intrinsic value of life sciences company Malin dips again

  • 📰 IrishTimes
  • ⏱ Reading Time:
  • 26 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 14%
  • Publisher: 98%

Malin أخبار

المملكة العربية السعودية أحدث الأخبار,المملكة العربية السعودية عناوين

State-backed company says decline is due in part to falling share price of Poseida

State-backed life sciences company Malin Corporation said its estimated intrinsic value per share continued to decline in the first half of the year, as the value of key investments fell.

The fall in value has been attributed to the reduced share price of Poseida, the Nasdaq-listed clinical stage biopharma company in which Malin holds a 12 per cent stake, and a reduction in the value of its 15 per cent interest in Viamet, along with foreign exchange movements.

However, the share capital reduction necessary to achieve this buyback must be approved by shareholders and confirmed by the High Court. Malin is holding an extraordinary general meeting in September on the matter.

 

شكرًا لك على تعليقك. سيتم نشر تعليقك بعد مراجعته.
لقد قمنا بتلخيص هذا الخبر حتى تتمكن من قراءته بسرعة. إذا كنت مهتمًا بالأخبار، يمكنك قراءة النص الكامل هنا. اقرأ أكثر:

 /  🏆 3. in SA

المملكة العربية السعودية أحدث الأخبار, المملكة العربية السعودية عناوين